Skip to content
Urokinase
Kinlytic (urokinase) is an enzyme pharmaceutical. Urokinase was first approved as Kinlytic on 1978-01-16. It is used to treat coronary thrombosis, myocardial infarction, pulmonary embolism, vascular graft occlusion, and venous thrombosis in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Urokinase
Tradename
Proper name
Company
Number
Date
Products
KinlyticurokinaseMicrobix BiosystemsN-21846 DISCN1978-01-16
3 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
coronary thrombosisEFO_1000883D003328I21
myocardial infarctionEFO_0000612D009203I21
pulmonary embolismEFO_0003827D011655I26
vascular graft occlusion—D006083—
venous thrombosisHP_0004936D020246I82.40
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
— B01: Antithrombotic agents
— B01A: Antithrombotic agents
— B01AD: Enzymes, antithrombotic
— B01AD04: Urokinase
HCPCS
Code
Description
J3364
Injection, urokinase, 5000 iu vial
J3365
Injection, iv, urokinase, 250,000 i.u. vial
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameUROKINASE
INNurokinase
Description
Urokinase-type plasminogen activator precursor (uPA) (U-plasminogen activator)
Classification
Enzyme
Drug classenzymes
Image (chem structure or protein)UROKINASE
Structure (InChI/SMILES or Protein Sequence)
>1C5N:H|Thrombin heavy chain IVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTENDLLVRIGKHSRTRYERNIEKISM LEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHPVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVL QVVNLPIVERPVCKDSTRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKYGFY THVFRLKKWIQKVIDQFGE >1C5N:L|Thrombin light chain TFGSGEADCGLRPLFEKKSLEDKTERELLESYIDGR
Identifiers
PDB1C5L, 1C5M, 1C5N, 1C5O, 1C5P, 1C5Q, 1C5R, 1C5S, 1C5T, 1C5U, 1C5V, 1C5W, 1C5X, 1C5Y, 1C5Z, 1EJN, 1F5K, 1F5L, 1F92, 1FV9, 1GI7, 1GI8, 1GI9, 1GJ7, 1GJ8, 1GJ9, 1GJA, 1GJB, 1GJC, 1GJD, 1KDU, 1LMW, 1O3P, 1O5A, 1O5B, 1O5C, 1OWD, 1OWE, 1OWH, 1OWI, 1OWJ, 1OWK, 1SC8, 1SQA, 1SQO, 1SQT, 1U6Q, 1URK, 1VJ9, 1VJA, 1W0Z, 1W10, 1W11, 1W12, 1W13, 1W14, 1YWH, 2ARQ, 2ARR, 2FAT, 2FD6, 2I9A, 2I9B, 2NWN, 2O8T, 2O8U, 2O8W, 2R2W, 2VIN, 2VIO, 2VIP, 2VIQ, 2VIV, 2VIW, 2VNT, 3BT1, 3BT2, 3IG6, 3KGP, 3KHV, 3KID, 3LAQ, 3M61, 3MHW, 3MWI, 3OX7, 3OY5, 3OY6, 3PB1, 3QN7, 3U73, 3U74, 4DVA, 4DW2, 4FU7, 4FU8, 4FU9, 4FUB, 4FUC, 4FUD, 4FUE, 4FUF, 4FUG, 4FUH, 4FUI, 4FUJ, 4GLY, 4H42, 4JK5, 4JK6, 4K24, 4MNV, 4MNW, 4MNX, 4MNY, 4OS1, 4OS2, 4OS4, 4OS5, 4OS6, 4OS7, 4QTI, 4X0W, 4X1N, 4X1P, 4X1Q, 4X1R, 4X1S, 4XSK, 4ZHL, 4ZHM, 4ZKN, 4ZKO, 4ZKR, 4ZKS, 5AO5, 5AO6, 5HDO, 5HGG, 5LHN, 5LHP, 5LHQ, 5LHR, 5LHS, 5WXF, 5WXO, 5WXP, 5WXQ, 5WXR, 5WXS, 5WXT, 5XG4, 5YC6, 5YC7, 5Z1C, 5ZA7, 5ZA8, 5ZA9, 5ZAE, 5ZAF, 5ZAG, 5ZAH, 5ZAJ, 5ZC5, 6A8G, 6A8N, 6AEX, 6AG2, 6AG3, 6AG7, 6AG9, 6JYP, 6JYQ, 6L04, 6L05, 6NMB, 6XVD, 7DZD, 7E17, 7V63, 7VM4, 7VM5, 7VM6, 7VM7
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL1201420
ChEBI ID—
PubChem CID—
DrugBankDB00013
UNII ID83G67E21XI (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 34,641 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1 adverse events reported
View more details